| Symbol | IRON |
|---|---|
| Name | DISC MEDICINE, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | United States |
| Telephone | (617) 674-9274 |
| Fax | — |
| — | |
| Website | https://www.discmedicine.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001816736 |
| Description | Disc Medicine Inc is a clinical-stage biopharmaceutical company that is dedicated to transforming the lives of patients with hematologic disorders. The company is building a portfolio of innovative therapeutic candidates that affect fundamental pathways of red blood cell biology. Disc Medicine is committed to developing treatments that empower and bring hope to the many patients who suffer from hematologic disease. The firms pipeline includes investigational product candidates that affect heme biosynthesis and iron metabolism. Additional info from NASDAQ: |
2026-08-07 21:32
Khara Rahul 🟡 adjusted position in 5.0K shares (1 derivative) of Disc Medicine, Inc. (IRON) at $80.00 Transaction Date: Aug 06, 2026 | Filing ID: 340543
Read more
2026-08-06 22:30
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
Read more
2026-08-01 16:27
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
Read more
2026-07-30 12:32
(30% Negative) DISC MEDICINE, INC. (IRON) Reports Q3 2026 Financial Results
Read more
2026-07-30 12:30
Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update
Read more
2026-07-07 20:32
📋 JONATHAN YU (Officer) plans to sell 10K shares of Disc Medicine, Inc. (at $77.01 each, total $770K) Filed: Jul 07, 2026 | ID: 006921
Read more
2026-06-30 21:49
Khara Rahul 🟡 adjusted position in 2.5K shares (2 derivative) of Disc Medicine, Inc. (IRON) at $75.00 Transaction Date: Jun 26, 2026 | Filing ID: 290902
Read more
2026-06-30 21:45
Yu Jonathan Yen-Wen 🟡 adjusted position in 300 shares (1 derivative) of Disc Medicine, Inc. (IRON) at $72.50 Transaction Date: Jun 26, 2026 | Filing ID: 290891
Read more
2026-06-26 20:32
📋 RAHUL KHARA (Officer) plans to sell 2K shares of Disc Medicine, Inc. (at $70.16 each, total $175K) Filed: Jun 26, 2026 | ID: 006558
Read more
2026-06-25 00:34
Yu Jonathan Yen-Wen 🟡 adjusted position in 9.7K shares (1 derivative) of Disc Medicine, Inc. (IRON) at $72.66 Transaction Date: Jun 22, 2026 | Filing ID: 281519
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07603401 | Expanded Access Program of Bitopertin For Participants With EPP or XLP | — | Erythropoietic Protoporphyria (EPP) | Available | — | — | ClinicalTrials.gov |
| NCT07368972 | Study of DISC-0974-201 in Participants With IBD and Anemia | Phase2 | Inflammatory Bowel Disease (IBD) | Recruiting | 2026-02-20 | 2027-03-01 | ClinicalTrials.gov |
| NCT07187973 | A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Dise… | Phase1 | Sickle Cell Disease | Recruiting | 2026-01-06 | 2027-10-01 | ClinicalTrials.gov |
| NCT06985147 | A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera… | Phase2 | Polycythemia Vera (PV) | Active_Not_Recruiting | 2025-08-12 | 2029-02-01 | ClinicalTrials.gov |
| NCT06910358 | Study of Bitopertin in Participants With EPP or XLP (APOLLO) | Phase3 | Erythropoietic Protoporphyria (EPP) | Active_Not_Recruiting | 2025-04-04 | 2026-10-01 | ClinicalTrials.gov |
| NCT06050915 | A Study of DISC-3405 in Healthy Volunteers | Phase1 | Healthy Volunteer | Completed | 2023-10-03 | 2024-07-09 | ClinicalTrials.gov |
| NCT05883748 | HELIOS: Open-Label, Long-Term Extension Study to Investigate the Safety, Tolera… | Phase2 | Erythropoietic Protoporphyria | Enrolling_By_Invitation | 2023-08-31 | 2028-06-01 | ClinicalTrials.gov |
| NCT05745883 | Study of DISC-0974 to Assess the Safety, Tolerability, PK and PD of DISC-0974 i… | Phase1 | Chronic Kidney Diseases | Completed | 2023-04-04 | 2026-01-16 | ClinicalTrials.gov |
| NCT05308472 | Study of Bitopertin to Evaluate the Safety, Tolerability, Efficacy, and PPIX Co… | Phase2 | Erythropoietic Protoporphyria | Completed | 2022-10-31 | 2024-08-23 | ClinicalTrials.gov |
| NCT05320198 | Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodyspla… | Phase1 | Myelofibrosis; Anemia | Recruiting | 2022-06-06 | 2027-06-01 | ClinicalTrials.gov |
| NCT04999527 | Study to Evaluate the Safety, Tolerability, PK and PD of DISC-0974 in Healthy S… | Phase1 | Healthy Volunteer | Completed | 2021-08-10 | 2022-06-30 | ClinicalTrials.gov |
Total clinical trials: 11
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| DISC-0974 | Other | Phase PHASE1 | Myelofibrosis; Anemia | RECRUITING | NCT05320198 |
| DISC-1459 | Other | Phase PHASE3 | Erythropoietic Protoporphyria (EPP) | ACTIVE_NOT_RECRUITING | NCT06910358 |
| Placebo | Other | Phase PHASE3 | Erythropoietic Protoporphyria (EPP) | ACTIVE_NOT_RECRUITING | NCT06910358 |
| DISC-1459 | Other | Phase PHASE2 | Erythropoietic Protoporphyria | ENROLLING_BY_INVITATION | NCT05883748 |
| DISC-1459 | Other | Preclinical | Erythropoietic Protoporphyria (EPP) | AVAILABLE | NCT07603401 |
| DISC-1459 | Other | Phase PHASE3 | Erythropoietic Protoporphyria (EPP) | ACTIVE_NOT_RECRUITING | NCT06910358 |
| Placebo | Other | Phase PHASE3 | Erythropoietic Protoporphyria (EPP) | ACTIVE_NOT_RECRUITING | NCT06910358 |
| Placebo | Other | Phase PHASE2 | Inflammatory Bowel Disease (IBD) | RECRUITING | NCT07368972 |
| DISC-0974 | Other | Phase PHASE2 | Inflammatory Bowel Disease (IBD) | RECRUITING | NCT07368972 |
| DISC-3405 | Other | Phase PHASE2 | Polycythemia Vera (PV) | ACTIVE_NOT_RECRUITING | NCT06985147 |
| DISC-1459 | Other | Phase PHASE3 | Erythropoietic Protoporphyria (EPP) | ACTIVE_NOT_RECRUITING | NCT06910358 |
| Placebo | Other | Phase PHASE3 | Erythropoietic Protoporphyria (EPP) | ACTIVE_NOT_RECRUITING | NCT06910358 |
| DISC-3405 | Other | Phase PHASE1 | Sickle Cell Disease | RECRUITING | NCT07187973 |
| DISC-1459 | Other | Phase PHASE2 | Erythropoietic Protoporphyria | ENROLLING_BY_INVITATION | NCT05883748 |
| DISC-0974 | Other | Phase PHASE1 | Myelofibrosis; Anemia | RECRUITING | NCT05320198 |
| DISC-1459 | Other | Preclinical | Erythropoietic Protoporphyria (EPP) | AVAILABLE | NCT07603401 |
| DISC-1459 | Other | Phase PHASE3 | Erythropoietic Protoporphyria (EPP) | ACTIVE_NOT_RECRUITING | NCT06910358 |
| Placebo | Other | Phase PHASE3 | Erythropoietic Protoporphyria (EPP) | ACTIVE_NOT_RECRUITING | NCT06910358 |
| Placebo | Other | Phase PHASE2 | Inflammatory Bowel Disease (IBD) | RECRUITING | NCT07368972 |
| DISC-0974 | Other | Phase PHASE2 | Inflammatory Bowel Disease (IBD) | RECRUITING | NCT07368972 |
| Placebo | Other | Phase PHASE2 | Inflammatory Bowel Disease (IBD) | RECRUITING | NCT07368972 |
| DISC-0974 | Other | Phase PHASE2 | Inflammatory Bowel Disease (IBD) | RECRUITING | NCT07368972 |
| DISC-1459 | Other | Preclinical | Erythropoietic Protoporphyria (EPP) | AVAILABLE | NCT07603401 |
| Placebo | Other | Phase PHASE2 | Inflammatory Bowel Disease (IBD) | RECRUITING | NCT07368972 |
| DISC-0974 | Other | Phase PHASE2 | Inflammatory Bowel Disease (IBD) | RECRUITING | NCT07368972 |
| DISC-1459 | Other | Phase PHASE2 | Erythropoietic Protoporphyria | ENROLLING_BY_INVITATION | NCT05883748 |
| DISC-1459 | Other | Preclinical | Erythropoietic Protoporphyria (EPP) | AVAILABLE | NCT07603401 |
| DISC-1459 | Other | Phase PHASE2 | Erythropoietic Protoporphyria | ENROLLING_BY_INVITATION | NCT05883748 |
| DISC-1459 | Other | Preclinical | Erythropoietic Protoporphyria (EPP) | AVAILABLE | NCT07603401 |
| DISC-1459 | Other | Phase PHASE3 | Erythropoietic Protoporphyria (EPP) | ACTIVE_NOT_RECRUITING | NCT06910358 |
| Placebo | Other | Phase PHASE3 | Erythropoietic Protoporphyria (EPP) | ACTIVE_NOT_RECRUITING | NCT06910358 |
| DISC-1459 | Other | Phase PHASE2 | Erythropoietic Protoporphyria | ENROLLING_BY_INVITATION | NCT05883748 |
| DISC-1459 | Other | Phase PHASE2 | Erythropoietic Protoporphyria | ENROLLING_BY_INVITATION | NCT05883748 |
| DISC-3405 | Other | Phase PHASE1 | Sickle Cell Disease | RECRUITING | NCT07187973 |
| DISC-1459 | Other | Phase PHASE3 | Erythropoietic Protoporphyria (EPP) | ACTIVE_NOT_RECRUITING | NCT06910358 |
| Placebo | Other | Phase PHASE3 | Erythropoietic Protoporphyria (EPP) | ACTIVE_NOT_RECRUITING | NCT06910358 |
| DISC-1459 | Other | Phase PHASE2 | Erythropoietic Protoporphyria | ENROLLING_BY_INVITATION | NCT05883748 |
| DISC-1459 | Other | Phase PHASE3 | Erythropoietic Protoporphyria (EPP) | ACTIVE_NOT_RECRUITING | NCT06910358 |
| Placebo | Other | Phase PHASE3 | Erythropoietic Protoporphyria (EPP) | ACTIVE_NOT_RECRUITING | NCT06910358 |
| DISC-3405 | Other | Phase PHASE2 | Polycythemia Vera (PV) | RECRUITING | NCT06985147 |
| DISC-1459 | Other | Preclinical | Erythropoietic Protoporphyria (EPP) | TEMPORARILY_NOT_AVAILABLE | NCT07603401 |
| DISC-3405 | Other | Phase PHASE1 | Sickle Cell Disease | RECRUITING | NCT07187973 |
| DISC-1459 | Other | Preclinical | Erythropoietic Protoporphyria (EPP) | TEMPORARILY_NOT_AVAILABLE | NCT07603401 |
| DISC-3405 | Other | Phase PHASE1 | Sickle Cell Disease | RECRUITING | NCT07187973 |
| DISC-1459 | Other | Preclinical | Erythropoietic Protoporphyria (EPP) | TEMPORARILY_NOT_AVAILABLE | NCT07603401 |
| DISC-3405 | Other | Phase PHASE1 | Sickle Cell Disease | RECRUITING | NCT07187973 |
| DISC-1459 | Other | Preclinical | Erythropoietic Protoporphyria (EPP) | TEMPORARILY_NOT_AVAILABLE | NCT07603401 |
| DISC-3405 | Other | Phase PHASE1 | Sickle Cell Disease | RECRUITING | NCT07187973 |
| DISC-1459 | Other | Preclinical | Erythropoietic Protoporphyria (EPP) | TEMPORARILY_NOT_AVAILABLE | NCT07603401 |
| DISC-3405 | Other | Phase PHASE1 | Sickle Cell Disease | RECRUITING | NCT07187973 |
| DISC-0974 | Other | Phase PHASE1 | Myelofibrosis; Anemia | RECRUITING | NCT05320198 |
| DISC-0974 | Other | Phase PHASE1 | Myelofibrosis; Anemia | RECRUITING | NCT05320198 |
| DISC-0974 | Other | Phase PHASE1 | Myelofibrosis; Anemia | RECRUITING | NCT05320198 |
| DISC-0974 | Other | Phase PHASE1 | Myelofibrosis; Anemia | RECRUITING | NCT05320198 |
| DISC-0974 | Other | Phase PHASE1 | Myelofibrosis; Anemia | RECRUITING | NCT05320198 |
| DISC-3405 | Other | Phase PHASE1 | Sickle Cell Disease | RECRUITING | NCT07187973 |
| DISC-0974 | Other | Phase PHASE1 | Myelofibrosis; Anemia | RECRUITING | NCT05320198 |
| DISC-3405 | Other | Phase PHASE1 | Sickle Cell Disease | RECRUITING | NCT07187973 |
| DISC-3405 | Other | Phase PHASE1 | Sickle Cell Disease | RECRUITING | NCT07187973 |
| DISC-3405 | Other | Phase PHASE1 | Sickle Cell Disease | RECRUITING | NCT07187973 |
| DISC-3405 | Other | Phase PHASE1 | Sickle Cell Disease | RECRUITING | NCT07187973 |
| DISC-3405 | Other | Phase PHASE1 | Sickle Cell Disease | RECRUITING | NCT07187973 |
| DISC-1459 | Other | Phase PHASE3 | Erythropoietic Protoporphyria (EPP) | ACTIVE_NOT_RECRUITING | NCT06910358 |
| Placebo | Other | Phase PHASE3 | Erythropoietic Protoporphyria (EPP) | ACTIVE_NOT_RECRUITING | NCT06910358 |
| DISC-1459 | Other | Phase PHASE3 | Erythropoietic Protoporphyria (EPP) | ACTIVE_NOT_RECRUITING | NCT06910358 |
| Placebo | Other | Phase PHASE3 | Erythropoietic Protoporphyria (EPP) | ACTIVE_NOT_RECRUITING | NCT06910358 |
| DISC-1459 | Other | Phase PHASE3 | Erythropoietic Protoporphyria (EPP) | ACTIVE_NOT_RECRUITING | NCT06910358 |
| Placebo | Other | Phase PHASE3 | Erythropoietic Protoporphyria (EPP) | ACTIVE_NOT_RECRUITING | NCT06910358 |
| DISC-1459 | Other | Phase PHASE3 | Erythropoietic Protoporphyria (EPP) | ACTIVE_NOT_RECRUITING | NCT06910358 |
| Placebo | Other | Phase PHASE3 | Erythropoietic Protoporphyria (EPP) | ACTIVE_NOT_RECRUITING | NCT06910358 |
| DISC-1459 | Other | Phase PHASE3 | Erythropoietic Protoporphyria (EPP) | ACTIVE_NOT_RECRUITING | NCT06910358 |
| Placebo | Other | Phase PHASE3 | Erythropoietic Protoporphyria (EPP) | ACTIVE_NOT_RECRUITING | NCT06910358 |
| DISC-1459 | Other | Phase PHASE3 | Erythropoietic Protoporphyria (EPP) | ACTIVE_NOT_RECRUITING | NCT06910358 |
| Placebo | Other | Phase PHASE3 | Erythropoietic Protoporphyria (EPP) | ACTIVE_NOT_RECRUITING | NCT06910358 |
| DISC-3405 | Other | Phase PHASE1 | Sickle Cell Disease | RECRUITING | NCT07187973 |
| DISC-3405 | Other | Phase PHASE1 | Sickle Cell Disease | RECRUITING | NCT07187973 |
| DISC-3405 | Other | Phase PHASE1 | Sickle Cell Disease | RECRUITING | NCT07187973 |
| DISC-3405 | Other | Phase PHASE1 | Sickle Cell Disease | RECRUITING | NCT07187973 |
| DISC-3405 | Other | Phase PHASE1 | Sickle Cell Disease | RECRUITING | NCT07187973 |
| DISC-3405 | Other | Phase PHASE1 | Sickle Cell Disease | RECRUITING | NCT07187973 |
| DISC-3405 | Other | Phase PHASE1 | Sickle Cell Disease | RECRUITING | NCT07187973 |
| DISC-3405 | Other | Phase PHASE1 | Sickle Cell Disease | RECRUITING | NCT07187973 |
| Placebo | Other | Phase PHASE2 | Inflammatory Bowel Disease (IBD) | RECRUITING | NCT07368972 |
| DISC-0974 | Other | Phase PHASE2 | Inflammatory Bowel Disease (IBD) | RECRUITING | NCT07368972 |
| Placebo | Other | Phase PHASE2 | Inflammatory Bowel Disease (IBD) | RECRUITING | NCT07368972 |
| DISC-0974 | Other | Phase PHASE2 | Inflammatory Bowel Disease (IBD) | RECRUITING | NCT07368972 |
| Placebo | Other | Phase PHASE2 | Inflammatory Bowel Disease (IBD) | RECRUITING | NCT07368972 |
| DISC-0974 | Other | Phase PHASE2 | Inflammatory Bowel Disease (IBD) | RECRUITING | NCT07368972 |
| Placebo | Other | Phase PHASE2 | Inflammatory Bowel Disease (IBD) | RECRUITING | NCT07368972 |
| DISC-0974 | Other | Phase PHASE2 | Inflammatory Bowel Disease (IBD) | RECRUITING | NCT07368972 |
| Placebo | Other | Phase PHASE2 | Inflammatory Bowel Disease (IBD) | RECRUITING | NCT07368972 |
| DISC-0974 | Other | Phase PHASE2 | Inflammatory Bowel Disease (IBD) | RECRUITING | NCT07368972 |
| Placebo | Other | Phase PHASE2 | Inflammatory Bowel Disease (IBD) | RECRUITING | NCT07368972 |
| DISC-0974 | Other | Phase PHASE2 | Inflammatory Bowel Disease (IBD) | RECRUITING | NCT07368972 |
| Placebo | Other | Phase PHASE2 | Inflammatory Bowel Disease (IBD) | RECRUITING | NCT07368972 |
| DISC-0974 | Other | Phase PHASE2 | Inflammatory Bowel Disease (IBD) | RECRUITING | NCT07368972 |
| Placebo | Other | Phase PHASE2 | Inflammatory Bowel Disease (IBD) | RECRUITING | NCT07368972 |
| DISC-0974 | Other | Phase PHASE2 | Inflammatory Bowel Disease (IBD) | RECRUITING | NCT07368972 |
| Placebo | Other | Phase PHASE2 | Inflammatory Bowel Disease (IBD) | RECRUITING | NCT07368972 |
| DISC-0974 | Other | Phase PHASE2 | Inflammatory Bowel Disease (IBD) | RECRUITING | NCT07368972 |
| Placebo | Other | Phase PHASE2 | Inflammatory Bowel Disease (IBD) | RECRUITING | NCT07368972 |
| DISC-0974 | Other | Phase PHASE2 | Inflammatory Bowel Disease (IBD) | RECRUITING | NCT07368972 |
| Placebo | Other | Phase PHASE2 | Inflammatory Bowel Disease (IBD) | RECRUITING | NCT07368972 |
| DISC-0974 | Other | Phase PHASE2 | Inflammatory Bowel Disease (IBD) | RECRUITING | NCT07368972 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT04999527 |
| DISC-0974 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT04999527 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06050915 |
| DISC-3405 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06050915 |
| Placebo | Other | Phase PHASE1 | Chronic Kidney Diseases | COMPLETED | NCT05745883 |
| DISC-0974 | Other | Phase PHASE1 | Chronic Kidney Diseases | COMPLETED | NCT05745883 |
| DISC-1459 | Other | Phase PHASE2 | Erythropoietic Protoporphyria | ENROLLING_BY_INVITATION | NCT05883748 |
| Placebo | Other | Phase PHASE2 | Erythropoietic Protoporphyria | COMPLETED | NCT05308472 |
| DISC-1459 | Other | Phase PHASE2 | Erythropoietic Protoporphyria | COMPLETED | NCT05308472 |
| DISC-3405 | Other | Phase PHASE2 | Polycythemia Vera (PV) | RECRUITING | NCT06985147 |
| DISC-0974 | Other | Phase PHASE1 | Myelofibrosis; Anemia | RECRUITING | NCT05320198 |
| DISC-3405 | Other | Phase PHASE1 | Sickle Cell Disease | RECRUITING | NCT07187973 |
| DISC-1459 | Other | Phase PHASE3 | Erythropoietic Protoporphyria (EPP) | ACTIVE_NOT_RECRUITING | NCT06910358 |
| Placebo | Other | Phase PHASE3 | Erythropoietic Protoporphyria (EPP) | ACTIVE_NOT_RECRUITING | NCT06910358 |
| Placebo | Other | Phase PHASE2 | Inflammatory Bowel Disease (IBD) | RECRUITING | NCT07368972 |
| DISC-0974 | Other | Phase PHASE2 | Inflammatory Bowel Disease (IBD) | RECRUITING | NCT07368972 |
| DISC-0974 | Other | Phase PHASE1 | Myelofibrosis; Anemia | RECRUITING | NCT05320198 |
| DISC-0974 | Other | Phase PHASE1 | Myelofibrosis; Anemia | RECRUITING | NCT05320198 |
| DISC-0974 | Other | Phase PHASE1 | Myelofibrosis; Anemia | RECRUITING | NCT05320198 |
| DISC-0974 | Other | Phase PHASE1 | Myelofibrosis; Anemia | RECRUITING | NCT05320198 |
| DISC-0974 | Other | Phase PHASE1 | Myelofibrosis; Anemia | RECRUITING | NCT05320198 |
| DISC-0974 | Other | Phase PHASE1 | Myelofibrosis; Anemia | RECRUITING | NCT05320198 |
| DISC-0974 | Other | Phase PHASE1 | Myelofibrosis; Anemia | RECRUITING | NCT05320198 |
| DISC-0974 | Other | Phase PHASE1 | Myelofibrosis; Anemia | RECRUITING | NCT05320198 |
| DISC-0974 | Other | Phase PHASE1 | Myelofibrosis; Anemia | RECRUITING | NCT05320198 |
| DISC-0974 | Other | Phase PHASE1 | Myelofibrosis; Anemia | RECRUITING | NCT05320198 |
| DISC-0974 | Other | Phase PHASE1 | Myelofibrosis; Anemia | RECRUITING | NCT05320198 |
| DISC-0974 | Other | Phase PHASE1 | Myelofibrosis; Anemia | RECRUITING | NCT05320198 |
| Placebo | Other | Phase PHASE1 | Chronic Kidney Diseases | COMPLETED | NCT05745883 |
| DISC-0974 | Other | Phase PHASE1 | Chronic Kidney Diseases | COMPLETED | NCT05745883 |
| Placebo | Other | Phase PHASE1 | Chronic Kidney Diseases | COMPLETED | NCT05745883 |
| DISC-0974 | Other | Phase PHASE1 | Chronic Kidney Diseases | COMPLETED | NCT05745883 |
| Placebo | Other | Phase PHASE1 | Chronic Kidney Diseases | COMPLETED | NCT05745883 |
| DISC-0974 | Other | Phase PHASE1 | Chronic Kidney Diseases | COMPLETED | NCT05745883 |
| Placebo | Other | Phase PHASE1 | Chronic Kidney Diseases | COMPLETED | NCT05745883 |
| DISC-0974 | Other | Phase PHASE1 | Chronic Kidney Diseases | COMPLETED | NCT05745883 |
| Placebo | Other | Phase PHASE1 | Chronic Kidney Diseases | COMPLETED | NCT05745883 |
| DISC-0974 | Other | Phase PHASE1 | Chronic Kidney Diseases | COMPLETED | NCT05745883 |
| Placebo | Other | Phase PHASE1 | Chronic Kidney Diseases | COMPLETED | NCT05745883 |
| DISC-0974 | Other | Phase PHASE1 | Chronic Kidney Diseases | COMPLETED | NCT05745883 |
| Placebo | Other | Phase PHASE1 | Chronic Kidney Diseases | COMPLETED | NCT05745883 |
| DISC-0974 | Other | Phase PHASE1 | Chronic Kidney Diseases | COMPLETED | NCT05745883 |
| Placebo | Other | Phase PHASE2 | Inflammatory Bowel Disease (IBD) | RECRUITING | NCT07368972 |
| DISC-0974 | Other | Phase PHASE2 | Inflammatory Bowel Disease (IBD) | RECRUITING | NCT07368972 |
| DISC-3405 | DRUG | Phase PHASE1 | Sickle Cell Disease | RECRUITING | NCT07187973 |
| DISC-1459 | DRUG | Phase PHASE3 | Erythropoietic Protoporphyria (EPP) | RECRUITING | NCT06910358 |
| Placebo | DRUG | Phase PHASE2 | Inflammatory Bowel Disease (IBD) | RECRUITING | NCT07368972 |
| DISC-0974 | DRUG | Phase PHASE2 | Inflammatory Bowel Disease (IBD) | RECRUITING | NCT07368972 |
Total products: 152